El Bachir Kaloun

This inventor holds 9 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 8 EPO patents. Top assignees: Pierre Fabre Medicament, Centre National De La Recherche Scientifique. Active years: 2014-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: El Bachir Kaloun. Retrieved from https://idiyas.com/inventor/el-bachir-kaloun

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 2)

% Patents Active = 55.6

CIPO Patents = 1

EPO Patents = 8 (Patent Applications = 12)

Average Co-Inventor Count = 5.2

ph-index = 1

Forward Citations = 49(Granted Patents)

Company Filing History:

9 out of 269

Pierre Fabre Medicament

patents

1 out of 5,383

Centre National De La Recherche Scientifique

patents

where one patent can have more than one assignee

Years Active: 2014-2020

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10544156 - Hemi-synthetic trilobine analogs for use as a drug (2020-01-28),

2. 10519125 - Flavagline derivatives (2019-12-31),

3. 10323043 - Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK (2019-06-18),

4. 10047064 - Flavagline derivatives (2018-08-14),

5. 9944641 - Isoquinolinone derivatives useful in the treatment of cancer (2018-04-17),

6. 9428510 - Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk (2016-08-30),

7. 9085575 - Tri- and tetracyclic pyrazolo[3,4-B]pyridine compounds as antineoplastic agent (2015-07-21),

8. 8889711 - Pyrazolopyridine derivatives as anticancer agent (2014-11-18),

9. 8883821 - Substituted pyrazolo[3,4-b]pyridines as medicaments (2014-11-11),

Title: El Bachir Kaloun: Innovator in Cancer Treatment

Introduction

El Bachir Kaloun is a prominent inventor based in Roquettes, France, known for his significant contributions to the field of pharmaceuticals. With a total of nine patents to his name, he has focused on developing innovative compounds aimed at treating cancer.

Latest Patents

Among his latest patents, Kaloun has developed Hemi-synthetic trilobine analogs for use as a drug. This invention concerns a compound that serves as a DNMT inhibitor, particularly in the treatment of cancer. Another notable patent involves Flavagline derivatives, which are compounds designed for use as medicaments, specifically targeting cancer treatment. These inventions highlight his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Kaloun has worked with esteemed organizations such as Pierre Fabre Medicament and the Centre National de la Recherche Scientifique. His experience in these institutions has allowed him to refine his expertise and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Throughout his career, Kaloun has collaborated with talented individuals, including Karim Bedjeguelal and Rémi Rabot. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

El Bachir Kaloun's work in developing novel compounds for cancer treatment underscores his role as a key innovator in the pharmaceutical field. His contributions continue to pave the way for advancements in medical therapies.

Profile summary based on public USPTO records.